This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.

Why It Matters

The combination of fresh capital, analyst upgrades, and a diversified pipeline positions CRSP for a potential turnaround, making it a focal point for growth‑oriented investors and biotech stakeholders.

Key Takeaways

• CRSP shares down 36% two‑year, yet ARK buying.
• Piper Sandler lifts target to $110, Overweight rating.
• Casgevy earned $116 M in 2025, pediatric expansion pending.
• CTX310 cuts LDL 49% and triglycerides 55% in Phase 1b.
• CTX611 targets clotting disorders, multi‑billion market potential.

Pulse Analysis

CRISPR Therapeutics sits at a crossroads where market sentiment and strategic capital intersect. While its share price has underperformed, the firm’s cash position—now exceeding $2.5 billion after a low‑coupon convertible note—provides a runway to fund multiple late‑stage programs without dilutive financing. Analysts view this balance sheet strength as a catalyst, especially as ARK’s continued buying signals confidence in the company’s long‑term innovation thesis.

The recent Piper Sandler upgrade underscores the financial community’s optimism. Raising the price target to $110 reflects confidence that the $600 million note, convertible at $76.56, will not only shore up liquidity but also lower the cost of capital. Coupled with the $116 million revenue from Casgevy, CRSP demonstrates an ability to translate breakthrough gene‑editing technology into commercial earnings, a rare feat in the biotech sector. The anticipated pediatric label expansion could further broaden the therapy’s addressable market, adding a new revenue vector.

Beyond Casgevy, CRSP’s pipeline diversification is its most compelling growth engine. CTX310’s early data showing a 49% LDL reduction and 55% triglyceride cut positions it as a potential challenger in lipid management, while CTX112’s autoimmune focus targets a multi‑billion SLE market. CTX611’s siRNA approach to Factor XI could disrupt clotting disorder treatments, tapping a lucrative therapeutic niche. Together, these programs suggest a multi‑year revenue uplift that could re‑energize the stock and validate the high‑risk, high‑reward model championed by investors like Cathie Wood.